| WELL |
Report |
Q2 2026 normalized FFO per share |
BEAT |
pred ~$1.58 vs. cons $1.55 |
MEDIUM |
| WELL |
Report |
Q2 2026 revenue |
BEAT |
pred ~$3.49B vs. cons $3.43B |
MEDIUM |
| WELL |
Report |
Q2 2026 SHO same-store NOI growth |
BEAT |
pred ~21.0% vs. cons 20.0% |
LOW |
| WELL |
Guide |
Normalized FFO per share |
BETTER |
guide ~$6.38 vs. cons $6.32 (FY2026 midpoint) |
MEDIUM |
| WELL |
Guide |
SHO same-store NOI growth |
BETTER |
guide ~20.0% vs. cons 19.5% (FY2026 midpoint) |
MEDIUM |
| WELL |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.4% |
— |
LOW |
| WELL |
Return |
5-day cumulative residual |
+2.3% (FOLLOW-THROUGH) |
FY2026 FFO guide of ~$6.38 less predicted H1 FFO of ~$3.05 implies H2 FFO of ~$3.33 vs. cons ~$3.30; modest positive out-period revisions should support follow-through, though WELL's premium valuation limits upside. |
LOW |